Spots Global Cancer Trial Database for ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Official Title: A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Study ID: NCT04319757
Study Description
Brief Summary: ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northwestern Univeristy, Chicago, Illinois, United States
MD Anderson Cancer Center, Houston, Texas, United States
Taipei Veteran General Hospital, Taipei, , Taiwan
Contact Details
Name: Michael Kurman, MD
Affiliation: Acepodia Biotech, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
